DTIL furnishes press release with Q3 2025 financial results

Rhea-AI Filing Summary

Precision BioSciences, Inc. furnished an update on its financials, announcing results for the quarter ended September 30, 2025. The company disclosed the information under Item 2.02 and provided the full details via a press release.

The press release is included as Exhibit 99.1, which is incorporated by reference. The company’s common stock trades on the Nasdaq Capital Market under the symbol DTIL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/03/2025 - 07:00 AM Learn about SEC filing dates

0001357874FALSE00013578742025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________

FORM 8-K

________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

________________________________________________________

Precision BioSciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

________________________________________________________

Delaware			001-38841			20-4206017
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
302 East Pettigrew St. Suite A-100
Durham, North Carolina						27701
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: 919 314-5512

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.000005 per share

DTIL

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press release of Precision BioSciences, Inc. dated November 3, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									PRECISION BIOSCIENCES, INC.
Date:			November 3, 2025			By:			/s/ John Alexander Kelly
									John Alexander Kelly Chief Financial Officer

FAQ

What did DTIL disclose in this 8-K?

The company announced its financial results for the quarter ended September 30, 2025, furnished under Item 2.02.

Where can I find the full financial details for DTIL?

The full text is available in the press release furnished as Exhibit 99.1 and incorporated by reference.

What is Precision BioSciences' trading symbol and exchange?

The common stock trades as DTIL on the Nasdaq Capital Market.

Which exhibit contains the press release?

Exhibit 99.1 contains the press release dated November 3, 2025.

Who signed the report for DTIL?

It was signed by John Alexander Kelly, Chief Financial Officer.